188 related articles for article (PubMed ID: 31151813)
1. Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study.
Russo V; Attena E; Mazzone C; Melillo E; Rago A; Galasso G; Riegler L; Parisi V; Rotunno R; Nigro G; D'Onofrio A
Clin Ther; 2019 Aug; 41(8):1598-1604. PubMed ID: 31151813
[TBL] [Abstract][Full Text] [Related]
2. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.
Rago A; Papa AA; Attena E; Parisi V; Golino P; Nigro G; Russo V
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1003-1007. PubMed ID: 32946035
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
[TBL] [Abstract][Full Text] [Related]
6. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Abozguia K; Grimaldi M; Rauer H; Reimitz PE; Smolnik R; Mönninghoff C; Kautzner J
Eur Heart J; 2019 Sep; 40(36):3013-3021. PubMed ID: 30976787
[TBL] [Abstract][Full Text] [Related]
7. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
Rago A; Papa AA; Cassese A; Arena G; Magliocca MCG; D'Onofrio A; Golino P; Nigro G; Russo V
Am J Cardiovasc Drugs; 2019 Aug; 19(4):421-427. PubMed ID: 30838557
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Dzeshka MS; Lip GY
Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
Russo V; Attena E; Rago A; Melillo E; Di Micco P; Papa AA; Napolitano G; D'Onofrio A; Golino P; Nigro G
J Clin Med; 2020 May; 9(6):. PubMed ID: 32471222
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
19. Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.
Goette A; Merino JL; De Caterina R; Huber K; Heidbuchel H; Jin J; Lip GYH
Clin Res Cardiol; 2020 Nov; 109(11):1374-1380. PubMed ID: 32236718
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
Russo V; Rago A; Papa AA; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2018 Feb; 45(2):206-212. PubMed ID: 29260427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
